Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Uniphar PLC ( (GB:UPR) ) has issued an announcement.
Uniphar plc announced its interim results for the first half of 2025, reporting a 21% growth in adjusted EPS and an 8.1% organic gross profit increase across all divisions. The company completed a €35 million share buyback and declared a 6% increase in interim dividends. Uniphar also extended its revolving credit facility and secured a €150 million term loan, reflecting its strategic focus on growth and expansion. With strong trading momentum, the company is well-positioned to meet its medium-term targets, including a projected €200 million EBITDA by 2028, primarily driven by organic growth.
More about Uniphar PLC
Headquartered in Dublin, Ireland, Uniphar plc is an international diversified healthcare services business that serves over 200 multinational pharmaceutical and medical technology manufacturers. Operating across three divisions—Uniphar Pharma, Uniphar Medtech, and Uniphar Supply Chain & Retail—the company is active in Europe, North America, APAC, and MENA, delivering to more than 160 countries. Uniphar aims to improve patient access to pharmaco-medical products by enhancing connectivity between manufacturers and healthcare stakeholders.
Learn more about UPR stock on TipRanks’ Stock Analysis page.